• TG Therapeutics (NasdaqCM:TGTX) published five year clinical data from the long term extension of its Phase 3 ULTIMATE studies for BRIUMVI in relapsing multiple sclerosis.
• The update reports durable efficacy, low relapse rates, and a consistent safety profile over the full five year period.
• The extension data also highlights long term treatment adherence and sustained clinical benefit for patients on BRIUMVI.

TG Therapeutics focuses on treatments for B cell mediated diseases, with BRIUMVI positioned as its key commercial product in relapsing multiple sclerosis. Five year extension results are relatively uncommon in this space and can be important for neurologists who want a clearer view of how therapies perform beyond the initial trial window.

For investors watching NasdaqCM:TGTX, this kind of long horizon data can shape how physicians view BRIUMVI compared with other options and may influence future prescribing patterns. The update also gives the medical community more information on long term safety, which can be a meaningful factor in chronic conditions such as multiple sclerosis.

Stay updated on the most important news stories for TG Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on TG Therapeutics.

For TG Therapeutics, five year data for BRIUMVI published in JAMA Neurology reinforces that its core commercial asset has long term clinical support, with low annualized relapse rates, high proportions of relapse free patients, and no new safety signals across more than 3,600 participant years. For a company that already reports BRIUMVI driven revenue of US$616.29 million for 2025 and has recently turned profitable, durable efficacy and safety can be important in discussions with neurologists who are comparing options against therapies from larger players such as Roche (Ocrevus) and Novartis (Kesimpta). The high treatment persistence in the extension study, with more than 70% of patients remaining on therapy at year 5, also speaks to adherence in a chronic disease where switching can be disruptive for patients and prescribers.

How This Fits Into The TG Therapeutics Narrative

• The long term BRIUMVI data supports the narrative that continued uptake and broader access could underpin revenue and margin expansion, especially as the company prepares for a potential subcutaneous version aimed at a bigger share of the anti CD20 market.
• The results also highlight the company’s reliance on one product, which the narrative already flags as a key issue, because any future change in physician preference or competing data from rivals such as Biogen could weigh heavily on the story.
• The narrative focuses heavily on future earnings scenarios and market access, while this publication adds extra clinical detail around disability progression and immunoglobulin stability that may not be fully reflected in those high level assumptions.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for TG Therapeutics to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Analysts have flagged that TG Therapeutics has a high level of non cash earnings, so the quality and sustainability of reported profit is worth watching even as BRIUMVI sales grow.
• ⚠️ The company remains heavily dependent on a single drug in a competitive multiple sclerosis market that includes established therapies from larger pharmaceutical groups.
• 🎁 TG Therapeutics is trading at what Simply Wall St’s model views as good value relative to peers and its industry, and is classified as trading well below that estimate of fair value.
• 🎁 The company only recently became profitable and is assessed as growing profit or revenue, which, combined with long term BRIUMVI data, gives shareholders a clearer business foundation to track.

What To Watch Going Forward

From here, you may want to track how quickly neurologists incorporate the five year BRIUMVI data into prescribing decisions, including any commentary on the Q4 2025 earnings call about new patient starts, switches from competitors, and retention. Competitive responses from companies behind other anti CD20 or oral MS therapies will also matter, particularly if they publish rival long term data. Finally, watch for further updates around any planned subcutaneous formulation and how payers react to long duration safety and efficacy outcomes when considering coverage and reimbursement terms.

To ensure you're always in the loop on how the latest news impacts the investment narrative for TG Therapeutics, head to the community page for TG Therapeutics to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.